In vitro antifungal activity of Zataria multiflora essential oil, fluconazole and ciclopirox olamine against nonalbicans Candida species isolated from recurrent vulvovaginal candidiasis

Document Type : Original Articles


1 Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

2 Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

3 Young Researchers & Elite Club, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran

4 Department of Microbiology, Karaj Branch, Islamic Azad University, Karaj, Iran.

5 Department of Biological Sciences, College of Sciences, Imam Hussein University, Tehran, Iran.

6 Faculty of pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

7 Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.


The aim of the present study was to investigate the antifungal activity of Zataria
multiflora essential oil, fluconazole and ciclopirox olamine against 44 non-albicans
Candida isolates from patients with recurrent vulvovaginal candidiasis. A set of C.
glabrata (29 strains), C. krusei (3 stains) and C. patapsilosis (2 strains) were studied
using Clinical and Laboratory Standards Institute (CLSI) broth macrodilution method.
The results revealed that 33 isolates were resistant (MIC=64 μg/ml), 4 isolates were
susceptible (MIC≤ 8 μg/ml) and 7 isolates had dose-dependent susceptibility (MIC= 16,
32 μg/ml) to fluconazole, respectively. With regard to fluconazole, high resistance rate
was observed in C .glabrata and C. krusei. However, ciclopirox olamine was found to
inhibit the growth of all non-albicans Candida species (MIC≤8 μg/ml). In this study,
favorable antifungal activity against non-albicans Candida species was obtained by Z.
multiflora despite having a wide range of MICs (34875-139500 μg/ml). The results
indicated that ciclopirox olamine and Z. multiflora might be promising in the treatment of
recurrent vulvovaginal candidiasis.


1. Asticcioli, S., Sacco, L., Daturi, R., Matti, C., Nucleo, E., Zara, F., Pagani, L., 2009. Trends in frequency and in vitro antifungal susceptibility patterns of Candida isolates from women attending the STD outpatients’ clinic of a tertiary care hospital in Northern Italy during the years 2002-2007. New
Microbiol, 32(2): 199-204.
2. Badiee, P., Alborzi, A., Davarpanah, M.A., Shakiba, E., 2010. Distributions and Antifungal Susceptibility of Candida Species from Mucosal Sites in HIV Positive Patients. Archives of Iranian medicine, 13(4): 282-287.
3. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard, 3rd ed, CLSI document M27-A3, Clinical and Laboratory Standards Institute, Wayne, PA. USA. (2008).
4. Czaika, V., Tietz, H.J., Schmalreck, A., Sterry, W., Schultze, W., 2000. Antifungal susceptibility testing in chronically recurrent vaginal candidosis as basis for effective therapy. Mycoses, 43: 45-50.
5. Faro S., 1996. New treatments for vulvovaginal candidiasis. Infect dis obstet gynecol, 4(4): 247-254.
6. Gupta, A.K., Plott, T., 2004. Ciclopirox: a broad-spectrum antifungal with antibacterial and anti-inflammatory properties. Int J Dermatol, 43 (1): 3-8.
7. Gupta, A.K., Kohli, Y., 2003. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. Br J Dermatol, 149(2): 296-305.
8. Hanel, H., Raether, W., Dittmar, W., 1988. Evaluation of fungicidal action in vitro and in a skin model considering the influence of penetration kinetics of various standard antimycotics. Ann NY Acad Sci, 544: 329-337.
9. Hosseinzadeh, H., Ramezani, M., salmani, G., 2000. Antinociceptive, anti-
inflammatory and acute toxicity effects of Zataria multiflora Boiss. extract in mice and rats. J Ethnopharmacole, 73: 379-385.
10. Gandomi, H., Misaghi, A., Akhondzadeh Basti, A., Hamedi, H., Ramezani Shirvani, Z., 2011. Effect of Zataria multiflora Boiss. essential oil on colony morphology and ultrastructure of Aspergillus flavus. Mycoses, 54 (5) : 429-437.
11. Kennedy, M.A., Sobel, J.D., 2010. Vulvovaginal candidiasis caused by non-albicans Candida species: new insights. Curr Infect Dis Rep, 12(6): 465-470.
12. Khosravi, A.R., Shokri, H., Tootian, Z., Alizadeh, M., Yahyaraeyat, R., 2009. Comparative efficacies of Zataria multiflora essential oil and itraconazole against disseminated Candida albicans infection in BALB/c mice. J.Microbiol, 40(3): 439-445.
13. Khosravi, A.R., Eslami, A.R., Shokri, H., Kashanian, M., 2008. Zataria multiflora cream for the treatment of acute vaginal candidiasis. Int J Gynaecol Obstet, 101(2) : 201-2.
14. Leem, S.H., Park, J.E., Kim, I.S., Chae, J.Y., Sugino, A., Sunwoo, Y., 2003. The possible mechanism of action of ciclopirox olamine in the yeast Saccharomyces cerevisiae. Mol Cells. 15:55-61.
15. Mahmoudabadi, A.Z., Dabbagh, M.A., Fouladi, Z., 2006. In vitro anti-Candida activity of Zataria multiflora boiss. eCAM, 4: 351-353.
16. Ozçelik, B., Balaban, N., Aksaray, S., Cesur, S., Kaynak, F., Çayırlı, A., 2006. In-vitro Susceptibility of Candida spp. Isolated from Clinical Specimens Against some Antifungal Agents. Turkish J Pharm Sci, 3(1): 8-16.
17. Pádua, R.A.F., Guilhermetti, E., Svidzinski, T.I.E., 2003. In vitro activity of antifungal agents on yeasts isolated from vaginal secretion. Acta Scientiarum, 25: 51-54.
18. Pfaller, M.A., Hata, K., Jones, R.N., Messer, S.A., Moet, G.J., Castanheira, M., 2011. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method. Diagn Microbiol Infect Dis, 71(2): 167-170.
19. Richter, S.S., Galask, R.P., Messer, S.A., Hollis, R.J., Diekema, D.J., Pfaller, M.A., 2005. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol, 43(5): 2155-2162.
20. Satana, D., Genc, G.E., Erturan, Z., Afr, J., 2010. The antifungal susceptibilities of oral Candida spp. isolates from HIV-infected patients. J Microbiol Res, 4(17): 1831-1835.
21. Simbar, M., Azarbad, Z., Mojab, F., Alavi Majd, H.A., 2008. Comparative Study of Therapeutic Effects of Zataria Multiflora Vaginal Cream and Metronidazole Vaginal Gel on Bacterial Vaginosis. Phytomedicine, 13(3): 193-202.
22. Sobel, J.D., 2006. Management of recurrent vulvovaginal candidiasis. Curr Infect Dis Rep, 8(6): 481-486.
23. Swinne, D., Watelle, M., Nolard, N., 2005. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates. Rev Iberoam Micol. 22(1): 24-28.
24. Trama, J.P., Adelson, M., Raphaelli, I., Stemmer, S., Mordechai, E., 2005. Detection of Candida species in vaginal samples in a clinical laboratory setting infect. Dis.Obstet Gynecol, 13: 63-67.
25. Watson, C., Pirotta, M., 2011, Recurrent vulvovaginal candidiasis current management. Aust Fam Physician, 40(3): 149-151.
26. Zaneveld, L.J.D., Waller, D.P., Sellors, J., Camus-Bablon, F., Ciclopirox olamine: A
vaginal product with Microbicide potential. Available on
27. Zomorodian, K., Saharkhiz, M.J., Rahimi, M.J., Bandegi, A., Shekarkhar, G., Bandegani, A., Pakshir, K., Bazargani, A., 2011. Chemical composition and antimicrobial activities of the essential oils from three ecotypes of Zataria multiflora. Pharmacognosy magazine, 7(25): 53-59.